5.3 Addressing translational challenges Despite these promising results, several challenges must be addressed to optimize SFNs clinical application
A critical barrier to addressing this challenge is the stark lack of approved pharmacotherapies for many liver disorders, as exemplified by the limited options for MASLD (Zhang and Yang, 2021)
Issues such as limited bioavailability, metabolic differences, and challenges in dose optimization can impact the efficacy of natural compounds in clinical settings compared to preclinical studies (Oyanna and Clarke 2024)
Its anti-inflammatory properties reduce local inflammation that contributes to barrier breakdown
doi: 10.3945/jn.109.106864 425 CozminMLunguIIGutuCStefanacheADuceacLDoltuzuBDet al
When both are activated simultaneously, the intracellular signalling cascades interact synergistically: CJC-1295 activates GHRHR increases intracellular cAMP activates protein kinase A enhances GH gene transcription and vesicle exocytosis
